.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,595,872

« Back to Dashboard

Details for Patent: 5,595,872

Title: Nucleic acids encoding microsomal trigyceride transfer protein
Abstract:Nucleic acid sequences, particularly DNA sequences, coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, and methods for producing these polypeptide molecules. The invention additionally concerns novel methods for preventing, stabilizing or causing regression of atherosclerosis and therapeutic agents having such activity. The invention concerns further novel methods for lowering serum liquid levels and therapeutic agents having such activity.
Inventor(s): Wetterau, II; John R. (Langhorne, PA), Sharp; Daru Y. (Perrineville, NJ), Gregg; Richard E. (Pennington, NJ), Biller; Scott A. (Ewing, NJ), Dickson; John K. (Mount Holly, NJ), Lawrence; R. Michael (Yardley, PA), Lawson; John E. (Wallingford, CT), Holava; Henry M. (Meriden, CT), Partyka; Richard A. (Neshanic, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Filing Date:Sep 03, 1993
Application Number:08/117,362
Claims:1. An isolated nucleic acid molecule consisting of an MTP nucleotide sequence, wherein the MTP nucleotide sequence encodes the high molecular weight subunit of microsomal triglyceride transfer protein.

2. The nucleic acid molecule according to claim 1 which is a DNA molecule.

3. The DNA molecule according to claim 2 consisting of all or part of the MTP nucleotide sequence, wherein said all or part is selected from SEQ. ID. NOS. 1, 2, 5, 7, 8, 1 together with 5, 2 together with 7, the first 108 bases of 2 together with 8, the first 108 bases of 2 together with 7 and 8, and 8 together with SEQ. ID, NOS. 31 and 32.

4. A DNA molecule having a nucleotide sequence fully complementary to the MTP nucleotide sequence of claim 1.

5. A DNA molecule having a nucleotide sequence fully complementary to the selected all or part of MTP nucleotide sequence of claim 3.

6. An expression vector comprising an MTP nucleotide sequence, wherein the MTP nucleotide sequence encodes the high molecular weight subunit of microsomal triglyceride transfer protein.

7. The expression vector according to claim 6 wherein the MTP nucleotide sequence is all or part of the MTP nucleotide sequence selected from SEQ. ID. NOS. 1, 2, 5, 7, 8, 1 together with 5, 2 together with 7, the first 108 bases of 2 together with 8, the first 108 bases of 2 together with 7 and 8, and 8 together with SEQ. ID. NOS. 31 and 32.

8. A prokaryotic or eukaryotic host cell comprising the expression vector according to claim 6.

9. A prokaryotic or eukaryotic host cell comprising the expression vector according to claim 7.

10. A method for detecting a nucleic acid having an MTP nucleotide sequence, which comprises:

(a) contacting said nucleic acid with a detectable marker consisting of a labeled nucleic acid sequence which binds specifically to at least part of the nucleic acid having an MTP nucleotide sequence, and

(b) detecting the marker so bound; wherein the presence of bound marker indicates the presence of the nucleic acid having an MTP nucleotide sequence, and wherein the MTP nucleotide sequence encodes the high molecular weight subunit of microsomal triglyceride transfer protein.

11. The method according to claim 10 wherein the detectable marker consists of a nucleotide sequence of 15 to 33 sequential nucleotides of SEQ. ID. NOS. 1, 2, 5, 7, 8, 1 together with 5, 2 together with 7, the first 108 bases of 2 together with 8, the first 108 bases of 2 together with 7 and 8, or 8 together with SEQ. ID. NOS. 31 and 32.

12. The method according to claim 10 wherein the detectable marker consists of a nucleotide sequence of 15 to 33 sequential nucleotides fully complementary to a nucleotide sequence selected from SEQ. ID. NOS. 1, 2, 5, 7, 8, 1 together with 5, 2 together with 7, the first 108 bases of 2 together with 8, the first 108 bases of 2 together with 7 and 8, and 8 together with SEQ. ID. NOS. 31 and 32.

13. The method according to claim 10 wherein the nucleic acid having an MTP nucleotide sequence is selected from the group consisting of genomic DNA, cDNA, and RNA.

14. The method according to claim 10 wherein the detectable marker is labeled with a radioisotope and the detecting step is carried out by autoradiography.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc